RxDB
ICD-9-CM Codes ICD-9-PCS Codes

9929 - Injection or infusion of other therapeutic or prophylactic substance

Overview

GEM Conversion to ICD-10 PCS

Fs: 10000 – Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach
Fs: 10000 – Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach
Fs: 10000 – Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach
Fs: 10000 – Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach
Fs: 10000 – Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach
Fs: 10000 – Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach
Fs: 10000 – Introduction of Immunostimulator into Peripheral Vein, Percutaneous
Fs: 10000 – Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach
Fs: 10000 – Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach
Fs: 10000 – Introduction of Radioactive Substance into Central Vein, Percutaneous Approach
Fs: 10000 – Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach
Fs: 10000 – Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach
Fs: 10000 – Introduction of Immunostimulator into Central Vein, Percutaneous
Fs: 10000 – Introduction of Destructive Agent into Peripheral Artery, Open Approach
Fs: 10000 – Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Immunostimulator into Peripheral Artery, Percutaneous
Fs: 10000 – Introduction of Destructive Agent into Central Artery, Open Approach
Fs: 10000 – Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach
Fs: 10000 – Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach
Fs: 10000 – Introduction of Radioactive Substance into Central Artery, Percutaneous Approach
Fs: 10000 – Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Central Artery, Percutaneous Approach
Fs: 10000 – Introduction of Immunostimulator into Central Artery, Percutaneous
Fs: 10000 – Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Nose, Percutaneous Approach
Fs: 10000 – Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Nose, External Approach
Fs: 10000 – Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach
Fs: 10000 – Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Mouth and Pharynx, External Approach
Fs: 10000 – Introduction of Destructive Agent into Upper GI, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Lower GI, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach
Fs: 10000 – Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach
Fs: 10000 – Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach
Fs: 10000 – Introduction of Destructive Agent into Lymphatics, Percutaneous Approach
Fs: 10000 – Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1
Fs: 10000 – Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1

Sibling Codes

Injection or infusion of platelet inhibitor
Injection of antibiotic
Injection of other anti-infective
Injection of steroid
Injection of other hormone
Injection or infusion of cancer chemotherapeutic substance
Injection of tranquilizer
Iontophoresis
Injection or infusion of biological response modifier [BRM] as an antineoplastic agent
Injection or infusion of other therapeutic or prophylactic substance